Solventum Corporation (SOLV)

Solventum beats Q1 estimates, raises guidance, and powers ahead with transformation despite looming tariff headwinds.

Solventum (SOLV) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, SOLV broke through the 200-day moving average, which suggests a lon...

Solventum Corporation (NYSE:SOLV ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Amy Wakeham - Senior Vice President of Investor Relations & External Finance Communicati...

Solventum Corporation's stock has dropped 20% since February despite beating earnings and revenue expectations in its last two quarterly reports. SOLV operates in four divisions: Medsurg, Dental Solut...

SOLV's first-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.

Although the revenue and EPS for Solventum (SOLV) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Stree...

Solventum (SOLV) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.19 per share. This compares to earnings of $2.08 per share a year ago.

3M spin-off Solventum beat analysts' estimate for first-quarter profit on Thursday, helped by higher sales of its wound care, sterilization products.

SOLV's Q1 performance is likely to have been hurt by below-par revenue growth in several markets, coupled with currency headwinds. Improved pricing might have offset the sales decline.

Investors looking for stocks in the Medical Services sector might want to consider either Solventum (SOLV) or Doximity (DOCS). But which of these two companies is the best option for those looking for...